Comprehensive CCTA Analysis
Complementary anatomical and physiological insights from
DEEPVESSEL FFR and DEEPVESSEL Plaque.
Comprehensive CCTA Analysis: understand physiology, quantify plaque and stenosis.
CT-Derived FFR Analysis
Functional assessment of coronary artery disease
DEEPVESSEL FFR is FDA-cleared, deep-learning-based software that calculates CT-derived FFR values from previously acquired CCTA data. It provides a color-coded 3D coronary model and branch-level FFR results to support qualified clinicians in evaluating the functional significance of coronary artery disease.
Coronary Plaque Analysis
Quantitative plaque assessment
DEEPVESSEL Plaque is FDA-cleared, AI-assisted software that characterizes and quantifies coronary plaque and stenosis from previously acquired CCTA data. It provides quantitative measurements and visual clinical reports to support qualified clinicians in coronary artery assessment.
Clinical validation. Complementary insights.
ADAPT Study
A multicenter U.S. and European study evaluated DEEPVESSEL FFR for detecting ischemia, using invasive FFR as the reference standard.
86.9%
Sensitivity
86.7%
Specificity
86.8%
Accuracy
91.9%
Negative predictive value
COMPOSE-CT Study
r = 0.976
Total plaque volume
r = 0.994
Calcified plaque volume
r = 0.945
Non-calcified plaque volume
0.810
CAD-RADS® weighted kappa
FFRCT and DVFFR have transformed my practice, allowing me to provide superior patient care and achieve better outcomes. I am sincerely grateful for this invaluable resource provided by Corazon Imaging.
News
Keya Medical to Participate in NASCI 2026
Meet Keya Medical at NASCI 2026 in Denver, September 26–29, and explore comprehensive CCTA analysis with DVFFR and DVPlaque.
Comprehensive CCTA Assessment with DEEPVESSEL FFR and Plaque Analysis
Explore how quantitative plaque analysis and CT-FFR complement stenosis assessment in CCTA, including insights from COMPOSE-CT and the SCCT 2026 expert webinar.
COMPOSE-CT Validates DEEPVESSEL Plaque Against Expert Consensus
The multicenter COMPOSE-CT study demonstrated strong agreement between FDA-cleared DEEPVESSEL Plaque and Level III expert consensus for coronary plaque quantification and CAD-RADS stenosis categorization.
For healthcare professionals in the United States